Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study

Alimentary Pharmacology & Therapeutics

Volumn 9, Issue 6, 1995, Pages 667-671

  CORINALDESI, R ^a   VALENTINI, M ^b   BELAICHE J ^c   COLIN, R ^d   GELDOF, H ^e   MAIER, C ^f  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d HÔPITAL CHARLES NICOLLE   (France)

^e IJSSELLAND HOSPITAL   (Netherlands)

^f ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PANTOPRAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; ENDOSCOPY; EUROPE; FEMALE; HEADACHE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; REFLUX ESOPHAGITIS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; BENZIMIDAZOLES; DOUBLE-BLIND METHOD; ESOPHAGITIS, PEPTIC; FEMALE; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SULFOXIDES;

EID: 0029565402     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1995.tb00437.x     Document Type: Article

References (19)

1. +)‐ATPase inhibitor
2. +‐ATPase
3. +‐ATPase‐inhibitor pantoprazole (BY 1023/SK&F96022) in healthy volunteers
4. Effect of repeated oral administration of BY1023/SK&P96022—a new substituted benzimidazole derivative—on pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man
5. Effect of oral pantoprazole on 24‐hour intragastric pH, serum gastrin profile and drug metabolizing enzyme activity in man—a placebo‐controlled comparison with ranitidine
6. 24h intragastric pH following oral intake of pantoprazole and omeprazole
7. Dose‐range finding study with the proton pump inhibitor Pantoprazole in acute duodenal ulcer patients
8. Effect of pantoprazole on 24‐h intragastric pH and serum gastrin in humans
9. BY1023/SK&F96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions
10. +‐ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole
11. Pantoprazole heals duodenal ulcer faster than ranitidin—European multicentre study
12. Role of gastric acid suppression in the treatment of gastro‐oesophageal reflux disease
13. Omeprazole (40 mg) is superior to ranitidine in short‐term treatment of ulcerative reflux esophagitis
14. Comparison of omeprazole (20 mg once a day) and ranitidine (150 mg twice a day) in the treatment of reflux oesophagitis. Results of a Franco‐Belgian randomized double‐blind multi‐centre trial
15. Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial
16. Omeprazole. An updated review of its pharmacology and therapeutic use in acid‐related disorders
17. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies
18. Clinical efficacy of pantoprazole compared with ranitidine
19. A double‐blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial